|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We utilized the adeno- ANT2 shRNA virus to inhibit ANT2 expression and then observed the treatment effect in a SP of breast cancer cell line.
|
22198296 |
2012 |
|
Fibrosis, Liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, ANT2 expression was significantly lower in the aged rat liver and in a liver fibrosis model.
|
22034909 |
2012 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
|
23242177 |
2013 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The data suggest that miR-636 might function as a tumor suppressor miRNA affecting HCC tumorigenesis via downregulation of Ras, and that ANT2 suppression by shRNA could exert an anticancer effect by restoring miR-636 expression in HCC.
|
23306701 |
2013 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the combined RNA interference with ANT2 and GCV therapy inhibited hepatocellular carcinoma cell proliferation more than single GCV therapy or ANT2 shRNA therapy in vitro and in vivo.
|
24054501 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We treated the tumor cells with ANT2 shRNA or GCV or both ANT2 shRNA and GCV and treated the in vivo mouse model with a Huh 7/NTG tumor xenograft.
|
24054501 |
2013 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Validation of candidate miRNAs was done by incorporating clinical samples, and their effects on the tumorigenesis of HCC were studied in vitro and in vivo. miR-636 was one of the miRNAs whose expression was highly upregulated by ANT2 suppression in miRNA microarray analysis, as confirmed by real-time reverse transcription-polymerase chain reaction.
|
23306701 |
2013 |
|
Refractory cancer
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In conclusion, the AME genes involved in aminoglycoside-clinical resistance were aac(3)-IIa, aac(6')-Ib, and ant(2″)-Ia, genes that confer resistance to tobramycin, gentamicin, and amikacin.
|
23206280 |
2013 |
|
Intellectual Disability
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, our findings point to SLC25A5 as a novel gene for non-syndromic ID.
|
23783460 |
2013 |
|
Cardiomyopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
Despite causing similar proteostatic damages, the adPEO- but not the cardiomyopathy/myopathy-type Aac2 proteins form large aggregates.
|
25833713 |
2015 |
|
Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ant2 depletion caused anemia in a cell-autonomous manner by maturation arrest of erythroid precursors with increased reactive oxygen species and premature deaths.
|
25613378 |
2015 |
|
Male infertility
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
While knockout mice have been characterized with Ant1 and Ant4 genes, which resulted in exercise intolerance and male infertility, respectively, the role of the ubiquitously expressed Ant2 gene in animal development has not been fully demonstrated.
|
25613378 |
2015 |
|
Myopathy
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Despite causing similar proteostatic damages, the adPEO- but not the cardiomyopathy/myopathy-type Aac2 proteins form large aggregates.
|
25833713 |
2015 |
|
Psoriasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Increases in gene expression for slc25a5 (1.8-fold), cystatin A (3-fold), KLK6 (5.8-fold), and serpinB1 (76-fold; all p < 0.05) were observed between healthy controls and involved lesional psoriasis skin and primary psoriasis keratinocytes.
|
25351201 |
2015 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings suggest that ANT2 overexpression contributes to EGFR-TKI resistance in NSCLC and that ANT2 targeting may be considered a novel strategy for overcoming this resistance.Mol Cancer Ther; 15(6); 1387-96.©2016 AACR.
|
26883272 |
2016 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings suggest that ANT2 overexpression contributes to EGFR-TKI resistance in NSCLC and that ANT2 targeting may be considered a novel strategy for overcoming this resistance.Mol Cancer Ther; 15(6); 1387-96.©2016 AACR.
|
26883272 |
2016 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Our data show that miR-19a and miR-96, whose expression is regulated by ANT2 suppression, were markedly upregulated in HCC cell lines and clinical samples.
|
27012708 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
|
27012708 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ANT2-specific shRNA decreased NSCLC cell viability.
|
26883272 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells.
|
28350139 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells.
|
28350139 |
2017 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
|
28350139 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells.
|
28350139 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 can be used as a marker of dedifferentiated pathology and aggressiveness of cancer.
|
30225759 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 can be used as a marker of dedifferentiated pathology and aggressiveness of cancer.
|
30225759 |
2019 |